File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term treatment of hyperprolactinaemia with bromocriptine: Effect of drug withdrawal

TitleLong-term treatment of hyperprolactinaemia with bromocriptine: Effect of drug withdrawal
Authors
Issue Date1987
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
Citation
Clinical Endocrinology, 1987, v. 27 n. 3, p. 363-371 How to Cite?
AbstractFifty-one patients with hyperprolactinaemia (23 with macroadenoma, 23 with microadenoma, and five with idiopathic hyperprolactinaemia) were treated with bromocriptine for 2-12 years (4.9 ± 2.9 years, mean ± SD). During therapy, the serum PRL levels were suppressed into the normal range in all but five patients. In these five patients, despite the high circulating PRL, gonadal function returned to normal in three, while in the other two gonadotrophin reserve was impaired even before therapy. Gel chromatography showed that one of these patients had a high proportion of a large molecular weight form of PRL. Twenty-four patients received bromocriptine as the sole method of treatment for over 2 years (3.4 ± 2.3 years). In five out of the 24 subjects (21%), serum PRL remained normal with no clinical symptoms after prolonged drug withdrawal (1-4 years). Twenty-one patients received radiotherapy in conjunction with bromocriptine therapy. Of these 11 had prior surgery. After a follow-up of 6.0 ± 3.0 years after radiotherapy, serum PRL remained within the normal range in 6 out of 21 subjects (29%), 1-4 years after bromocriptine withdrawal. One of the patients had impaired GH response to insulin hypoglycaemia developing after radiotherapy. We conclude that prolonged bromocriptine treatment is an effective treatment for prolactinomas.
Persistent Identifierhttp://hdl.handle.net/10722/161732
ISSN
2015 Impact Factor: 3.487
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Cen_US
dc.contributor.authorLam, KSLen_US
dc.contributor.authorMa, JTCen_US
dc.contributor.authorChan, Ten_US
dc.contributor.authorLiu, MYen_US
dc.contributor.authorYeung, RTTen_US
dc.date.accessioned2012-09-05T05:14:30Z-
dc.date.available2012-09-05T05:14:30Z-
dc.date.issued1987en_US
dc.identifier.citationClinical Endocrinology, 1987, v. 27 n. 3, p. 363-371en_US
dc.identifier.issn0300-0664en_US
dc.identifier.urihttp://hdl.handle.net/10722/161732-
dc.description.abstractFifty-one patients with hyperprolactinaemia (23 with macroadenoma, 23 with microadenoma, and five with idiopathic hyperprolactinaemia) were treated with bromocriptine for 2-12 years (4.9 ± 2.9 years, mean ± SD). During therapy, the serum PRL levels were suppressed into the normal range in all but five patients. In these five patients, despite the high circulating PRL, gonadal function returned to normal in three, while in the other two gonadotrophin reserve was impaired even before therapy. Gel chromatography showed that one of these patients had a high proportion of a large molecular weight form of PRL. Twenty-four patients received bromocriptine as the sole method of treatment for over 2 years (3.4 ± 2.3 years). In five out of the 24 subjects (21%), serum PRL remained normal with no clinical symptoms after prolonged drug withdrawal (1-4 years). Twenty-one patients received radiotherapy in conjunction with bromocriptine therapy. Of these 11 had prior surgery. After a follow-up of 6.0 ± 3.0 years after radiotherapy, serum PRL remained within the normal range in 6 out of 21 subjects (29%), 1-4 years after bromocriptine withdrawal. One of the patients had impaired GH response to insulin hypoglycaemia developing after radiotherapy. We conclude that prolonged bromocriptine treatment is an effective treatment for prolactinomas.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664en_US
dc.relation.ispartofClinical Endocrinologyen_US
dc.subject.meshAdenoma - Secretion - Therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshBromocriptine - Therapeutic Useen_US
dc.subject.meshCombined Modality Therapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHyperprolactinemia - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshPituitary Neoplasms - Secretion - Therapyen_US
dc.subject.meshProlactin - Blood - Secretionen_US
dc.subject.meshTime Factorsen_US
dc.titleLong-term treatment of hyperprolactinaemia with bromocriptine: Effect of drug withdrawalen_US
dc.typeArticleen_US
dc.identifier.emailLam, KSL:ksllam@hku.hken_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2265.1987.tb01163.x-
dc.identifier.pmid3427794en_US
dc.identifier.scopuseid_2-s2.0-0023269440en_US
dc.identifier.volume27en_US
dc.identifier.issue3en_US
dc.identifier.spage363en_US
dc.identifier.epage371en_US
dc.identifier.isiWOS:A1987J886000009-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridWang, C=7501631357en_US
dc.identifier.scopusauthoridLam, KSL=8082870600en_US
dc.identifier.scopusauthoridMa, JTC=24491943700en_US
dc.identifier.scopusauthoridChan, T=7402687762en_US
dc.identifier.scopusauthoridLiu, MY=7406297533en_US
dc.identifier.scopusauthoridYeung, RTT=7102833337en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats